Aptatek's Undisclosed Initial Close Funds PheCheck's Clinical Evaluation

Aptatek Biosciences, a Princeton, New Jersey clinical-stage diagnostics company, has announced the initial close of an undisclosed financing round led by Canterbury Scientific Ltd. and Longview Innovation. The company will use the proceeds to support the clinical evaluation and continued development of PheCheck, its investigational system for quantitative phenylalanine monitoring at home.

PheCheck is the first application of Aptatek's connected HomeCheck platform. The system combines DNA aptamer sensing, a reusable handheld reader, a single-use cartridge, and a smartphone-connected application. Aptatek is developing it for people living with phenylketonuria, or PKU, who may need lifelong monitoring of blood phenylalanine levels to guide diet, medication, and clinical care.

Aptatek did not disclose the amount, valuation, security type, final-close target, or complete syndicate, so the transaction cannot be safely labeled as a Seed, Series A, or final close. What is clear is the purpose: the proceeds are directed toward the clinical evaluation and continued development of PheCheck, and the evidence needed for a planned FDA regulatory submission.

PheCheck has received FDA Breakthrough Device designation, but it remains investigational, has not been cleared or approved by the FDA, and is not commercially available. Aptatek expects its ongoing clinical study to finish before the end of 2026 and plans to use the data in a future regulatory submission. The company says it has already completed preclinical analytical work that included comparison with LC-MS reference testing. Its registered validation study, NCT07551921, is evaluating rapid quantitative phenylalanine measurement from fingerstick blood samples in people with PKU or hyperphenylalaninemia.

The financing arrives at the point where Aptatek's core argument has to move from product design into clinical evidence. That distinction matters: the initial close supports the evidence-generation phase. It does not establish clinical performance, regulatory clearance, commercial availability, reimbursement, or adoption.

PKU is an inherited metabolic disorder in which phenylalanine can accumulate to harmful levels. Treatment can require lifelong dietary management, frequent blood testing, and regular clinical follow-up. Blood samples may be collected at home and mailed to a laboratory, which separates sample collection from the result used by a patient and care team. Aptatek is trying to change that information flow. PheCheck is designed to pair a fingerstick sample with a single-use cartridge, portable reader, and connected application. The company says the system can preserve measurements over time and share them with authorized care teams, potentially bringing quantitative information closer to the decisions it supports.